Treatment of myasthenia gravis by preventing acetylcholine receptor modulation

Annals of the New York Academy of Sciences

Volumn 1132, Issue , 2008, Pages 174-179

  Losen, Mario ^a,b   Martínez Martínez, Pilar ^a,b   Phernambucq, Marko ^a,b   Schuurman, Janine ^c   Parren, Paul W H I ^c   De Baets, Marc H ^a,b,d  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b European Graduate School   (Switzerland)

^c GENMAB   (Netherlands)

^d HASSELT UNIVERSITY   (Belgium)

Author keywords

Antigenic modulation; Complement; IgG4; Rapsyn

Indexed keywords

CHOLINERGIC RECEPTOR; IMMUNOGLOBULIN G4; RAPSYN;

ANIMAL MODEL; ANTIGENIC MODULATION; CONFERENCE PAPER; DISEASE ACTIVITY; HUMAN; MYASTHENIA GRAVIS; NEUROMODULATION; NONHUMAN; PROPHYLAXIS; PROTEIN EXPRESSION; RAT;

EID: 45249113754     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1405.034     Document Type: Conference Paper

References (47)

1. Patrick, J. & J. Lindstrom. 1973. Autoimmune response to acetylcholine receptor. Science 180 : 871 872.
2. Simpson, J.A. 1960. Myathenia gravis: a new hypothesis. Scottish Med. J. 5 : 419 436.
3. Hoch, W. et al. 2001. Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7 : 365 368.
4. Lavrnic, D. et al. 2005. The features of myasthenia gravis with autoantibodies to MuSK. J. Neurol. Neurosurg. Psychiatry 76 : 1099 1102.
5. Farrugia, M.E. et al. 2006. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 129 : 1481 1492.
6. Irani, S. & B. Lang. 2008. Autoantibody-mediated disorders of the central nervous system. Autoimmunity 41 : 55 65.
7. Rodgaard, A. et al. 1987. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin. Exp. Immunol. 67 : 82 88.
8. Chamberlain-Banoub, J. et al. 2006. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin. Exp. Immunol. 146 : 278 286.
9. Lennon, V.A. et al. 1978. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 147 : 973 983.
10. Tuzun, E. et al. 2003. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J. Immunol. 171 : 3847 3854.
11. Kao, I. & D.B. Drachman. 1977. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science 196 : 527 529.
12. Heinemann, S. et al. 1977. Modulation of acetylcholine receptor by antibody against the receptor. Proc. Natl. Acad. Sci. USA 74 : 3090 3094.
13. Loutrari, H., A. Kokla & S.J. Tzartos. 1992. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur. J. Immunol. 22 : 2449 2452.
14. Martinez-Martinez, P. et al. 2007. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis. Am. J. Pathol. 170 : 644 657.
15. Lang, B. et al. 1988. Plasma from myasthenia gravis patients reduces acetylcholine receptor agonist-induced Na+ flux into TE671 cell line. J. Neuroimmunol. 19 : 141 148.
16. Almon, R.R., C.G. Andrew & S.H. Appel. 1974. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science 186 : 55 57.
17. Gomez, C.M. & D.P. Richman. 1983. Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc. Natl. Acad. Sci. USA 80 : 4089 4093.
18. De Baets, M. et al. 2003. Immunoregulation in experimental autoimmune myasthenia gravis - about T cells, antibodies, and endplates. Ann. N.Y. Acad. Sci. 998 : 308 317.
19. Tarrab-Hazdai, R. et al. 1975. Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor. Nature 256 : 128 130.
20. Lindstrom, J.M. et al. 1976. Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects. Ann. N.Y. Acad. Sci. 274 : 254 274.
21. Toyka, K.V. et al. 1977. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N. Engl. J. Med. 296 : 125 131.
22. Toyka, K.V. et al. 1975. Myasthenia gravis: passive transfer from man to mouse. Science 190 : 397 399.
23. Lindstrom, J.M. et al. 1976. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J. Exp. Med. 144 : 739 753.
24. Tzartos, S.J. & J.M. Lindstrom. 1980. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc. Natl. Acad. Sci. USA 77 : 755 759.
25. Tzartos, S.J., M.E. Seybold & J.M. Lindstrom. 1982. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 79 : 188 192.
26. Tzartos, S.J. et al. 1998. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol. Rev. 163 : 89 120.
27. Tzartos, S.J. et al. 1991. The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies. Mol. Neurobiol. 5 : 1 29.
28. Guyon, T. et al. 1998. Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss. J. Clin. Invest. 102 : 249 263.
29. Kaminski, H.J. et al. 2004. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp. Neurol. 189 : 333 342.
30. Verschuuren, J.J. et al. 1991. Paratope- and framework-related cross-reactive idiotopes on anti-acetylcholine receptor antibodies. J. Immunol. 146 : 941 948.
31. Souroujon, M.C., A.R. Pachner & S. Fuchs. 1986. The treatment of passively transferred experimental myasthenia with anti-idiotypic antibodies. Neurology 36 : 622 625.
32. Luo, G.X. et al. 2001. Identification of a peptide that protects the human acetylcholine receptor against antigenic modulation. J. Immunol. Methods 251 : 177 186.
33. Wang, Z.Y., J. Qiao & H. Link. 1993. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J. Neuroimmunol. 44 : 209 214.
34. Im, S.H. et al. 2001. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J. 15 : 2140 2148.
35. Wu, J.M. et al. 2001. Specific immunotherapy of experimental myasthenia gravis in vitro: the "guided missile" strategy. Cell Immunol. 208 : 137 147.
36. Phillips, W.D. et al. 1997. Rapsyn and agrin slow the metabolic degradation of the acetylcholine receptor. Mol. Cell Neurosci. 10 : 16 26.
37. Wang, Z.Z. et al. 1999. Metabolic stabilization of muscle nicotinic acetylcholine receptor by rapsyn. J. Neurosci. 19 : 1998 2007.
38. Hoedemaekers, A. et al. 1998. Role of the target organ in determining susceptibility to experimental autoimmune myasthenia gravis. J. Neuroimmunol. 89 : 131 141.
39. Gervasio, O.L., P.F. Armson & W.D. Phillips. 2007. Developmental increase in the amount of rapsyn per acetylcholine receptor promotes postsynaptic receptor packing and stability. Dev. Biol. 305 : 262 275.
40. Gervasio, O.L. & W.D. Phillips. 2005. Increased ratio of rapsyn to ACh receptor stabilizes postsynaptic receptors at the mouse neuromuscular synapse. J. Physiol. 562 : 673 685.
41. Losen, M. et al. 2005. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain 128 : 2327 2337.
42. Papanastasiou, D. et al. 2000. Prevention of passively transferred experimental autoimmune myasthenia gravis by Fab fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor. J. Neuroimmunol. 104 : 124 132.
43. Richman, D.P. et al. 1998. Antibody effector mechanisms in myasthenia gravis. The complement hypothesis. Ann. N.Y. Acad. Sci. 841 : 450 465.
44. Toyka, K.V. et al. 1980. Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human myasthenic IgG. J. Neurol. Neurosurg. Psychiatry 43 : 836 840.
45. Van Der Neut Kolfschoten, M. et al. 2007. Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange. Science 317 : 1554 1557.
46. Graus, Y.F. et al. 1997. Anti-acetylcholine receptor Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. Immunol. Lett. 57 : 59 62.
47. Berman, P.W. & S.F. Heinemann. 1984. Antigenic modulation of junctional acetylcholine receptor is not sufficient to account for the development of myasthenia gravis in receptor immunized mice. J. Immunol. 132 : 711 717.